155 related articles for article (PubMed ID: 12121733)
21. Expression and purification of prostate-specific membrane antigen in the baculovirus expression system and recognition by prostate-specific membrane antigen-specific T cells.
Lodge PA; Childs RA; Monahan SJ; McLean JG; Sehgal A; Boynton AL; Salgaller ML; Murphy GP
J Immunother; 1999 Jul; 22(4):346-55. PubMed ID: 10404436
[TBL] [Abstract][Full Text] [Related]
22. Successful in vivo tumor targeting of prostate-specific membrane antigen with a highly efficient J591/PEI/DNA molecular conjugate.
Moffatt S; Papasakelariou C; Wiehle S; Cristiano R
Gene Ther; 2006 May; 13(9):761-72. PubMed ID: 16453011
[TBL] [Abstract][Full Text] [Related]
23. Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues.
Chang SS; Reuter VE; Heston WD; Hutchinson B; Grauer LS; Gaudin PB
Cancer; 2000 Jan; 88(2):407-15. PubMed ID: 10640975
[TBL] [Abstract][Full Text] [Related]
24. High expression of PSM-E correlated with tumor grade in prostate cancer: a new alternatively spliced variant of prostate-specific membrane antigen.
Cao KY; Mao XP; Wang DH; Xu L; Yuan GQ; Dai SQ; Zheng BJ; Qiu SP
Prostate; 2007 Dec; 67(16):1791-800. PubMed ID: 17929272
[TBL] [Abstract][Full Text] [Related]
25. Production of nanobodies against prostate-specific membrane antigen (PSMA) recognizing LnCaP cells.
Zare H; Rajabibazl M; Rasooli I; Ebrahimizadeh W; Bakherad H; Ardakani LS; Gargari SL
Int J Biol Markers; 2014 Jun; 29(2):e169-79. PubMed ID: 24425321
[TBL] [Abstract][Full Text] [Related]
26. A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses.
Durso RJ; Andjelic S; Gardner JP; Margitich DJ; Donovan GP; Arrigale RR; Wang X; Maughan MF; Talarico TL; Olmsted RA; Heston WD; Maddon PJ; Olson WC
Clin Cancer Res; 2007 Jul; 13(13):3999-4008. PubMed ID: 17606734
[TBL] [Abstract][Full Text] [Related]
27. Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses.
Ferraro B; Cisper NJ; Talbott KT; Philipson-Weiner L; Lucke CE; Khan AS; Sardesai NY; Weiner DB
Hum Vaccin; 2011; 7 Suppl():120-7. PubMed ID: 21266849
[TBL] [Abstract][Full Text] [Related]
28. PSMA specific antibodies and their diagnostic and therapeutic use.
Holmes EH
Expert Opin Investig Drugs; 2001 Mar; 10(3):511-9. PubMed ID: 11227049
[TBL] [Abstract][Full Text] [Related]
29. Analysis of glycosylation of prostate-specific membrane antigen derived from LNCaP cells, prostatic carcinoma tumors, and serum from prostate cancer patients.
Holmes EH; Greene TG; Tino WT; Boynton AL; Aldape HC; Misrock SL; Murphy GP
Prostate Suppl; 1996; 7():25-9. PubMed ID: 8950359
[TBL] [Abstract][Full Text] [Related]
30. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.
Elsässer-Beile U; Reischl G; Wiehr S; Bühler P; Wolf P; Alt K; Shively J; Judenhofer MS; Machulla HJ; Pichler BJ
J Nucl Med; 2009 Apr; 50(4):606-11. PubMed ID: 19289418
[TBL] [Abstract][Full Text] [Related]
31. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
[TBL] [Abstract][Full Text] [Related]
32. Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity.
Kuroda K; Liu H; Kim S; Guo M; Navarro V; Bander NH
Prostate; 2010 Sep; 70(12):1286-94. PubMed ID: 20623630
[TBL] [Abstract][Full Text] [Related]
33. Antitumor effect of dendritic cells transfected with prostate-specific membrane antigen recombinant adenovirus on prostate cancer: An in vitro study.
Meng FD; Wang S; Jiang YH; Sui CG
Mol Med Rep; 2016 Mar; 13(3):2124-34. PubMed ID: 26783185
[TBL] [Abstract][Full Text] [Related]
34. Targeting gene therapy for prostate cancer cells by liposomes complexed with anti-prostate-specific membrane antigen monoclonal antibody.
Ikegami S; Yamakami K; Ono T; Sato M; Suzuki S; Yoshimura I; Asano T; Hayakawa M; Tadakuma T
Hum Gene Ther; 2006 Oct; 17(10):997-1005. PubMed ID: 17032155
[TBL] [Abstract][Full Text] [Related]
35. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
36. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine.
Sokoloff RL; Norton KC; Gasior CL; Marker KM; Grauer LS
Prostate; 2000 May; 43(2):150-7. PubMed ID: 10754531
[TBL] [Abstract][Full Text] [Related]
37. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Igawa T; Lin FF; Rao P; Lin MF
Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
[TBL] [Abstract][Full Text] [Related]
38. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.
Li Y; Tian Z; Rizvi SM; Bander NH; Allen BJ
Prostate Cancer Prostatic Dis; 2002; 5(1):36-46. PubMed ID: 15195129
[TBL] [Abstract][Full Text] [Related]
39. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids.
Troyer JK; Beckett ML; Wright GL
Int J Cancer; 1995 Sep; 62(5):552-8. PubMed ID: 7665226
[TBL] [Abstract][Full Text] [Related]
40. Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo.
Medin JA; Liang SB; Hou JW; Kelley LS; Peace DJ; Fowler DH
Cancer Gene Ther; 2005 Jun; 12(6):540-51. PubMed ID: 15678150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
